Trading Signals: ADMS Stock Price Prediction and Forecast (Thu. Apr. 10, 2014 - Mon. Aug. 9, 2021)(Adamas Pharmaceuticals Inc)
| ADMS latest price $6.2500 (-4.29%) ($6.2100 - $6.6600) on Wed. Dec. 11, 2019. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 5.65% (three month average) | RSI | 77 | Latest Price | $6.2500(-4.29%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADMS declines -0.5% a day on average for past five trading days. | Weekly Trend | ADMS advances 8.5% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Normal for small cap. | Correlated ETFs | Broad market will support ADMS advance at 0% a week (0% probability) IGOV(12%) UNG(11%) BWX(7%) SLV(5%) VIXM(4%) | Factors Impacting ADMS price | ADMS will decline at least -2.825% in a week (0% probabilities). URA(-21%) BLOK(-16%) XLE(-15%) XLK(-14%) ACES(-14%) | | | | | Relative Volatility | | | | Market Trend Strength | -2.825% (StdDev 5.65%) | Hourly BBV | 0 () | Intraday Trend | -3.8% | | | |
|
5 Day Moving Average | $6.48(-3.55%) | 10 Day Moving Average | $6.32(-1.11%) | 20 Day Moving Average | $5.93(5.4%) | To recent high | -16.2% | To recent low | 22.1% | Market Cap | $177m | | | | Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. |